Hsp90 is an established anti-apoptotic target in cancer therapy.1 Most of the known small-molecule inhibitors that have shown potent antitumor activity target the Hsp90 N-terminal domain and directly inhibit its ATP-ase activity.2 However, many of these molecules display important secondary effects. A different approach to Hsp90 inhibition consists of targeting the protein C-terminal domain (CTD) and modulating its chaperone activity through allosteric effects. Using an original computational approach, allosteric hot-spots in the CTD have been recently identified that control interdomain communication.3 A combination of virtual and experimental screening enabled identification of 1 (Eupomatenoid-2, Figure 1) as a lead for further development.3 Four diversification areas have been identified (R1-R4, Figure 1). Chemical approaches to the (glyco)diversification at R4 will be presented,4 along with alternative synthetic pathways for the synthesis of the 2-phenyl-benzofuran core and its diversification at R1. Preliminary results indicate that the compounds obtained so far are CTD ligands and are able to modulate Hsp90 activity.
Towards allosteric modulators of Hsp90 / S. Sattin, L. Morelli, M. Panza, G. Vettoretti, E. Moroni, G. Colombo, A. Bernardi. ((Intervento presentato al 7. convegno International Conference on the Hsp90 Chaperone Machine tenutosi a Seeon Abbey nel 2014.
|Titolo:||Towards allosteric modulators of Hsp90|
SATTIN, SARA (Primo)
MORELLI, LAURA (Secondo)
BERNARDI, ANNA (Ultimo)
|Data di pubblicazione:||17-ott-2014|
|Settore Scientifico Disciplinare:||Settore CHIM/06 - Chimica Organica|
|Citazione:||Towards allosteric modulators of Hsp90 / S. Sattin, L. Morelli, M. Panza, G. Vettoretti, E. Moroni, G. Colombo, A. Bernardi. ((Intervento presentato al 7. convegno International Conference on the Hsp90 Chaperone Machine tenutosi a Seeon Abbey nel 2014.|
|Appare nelle tipologie:||14 - Intervento a convegno non pubblicato|